Pediatric Targeted Therapy 2.0 (PTT2.0)– refining diagnosis and analyzing targets in progressive and relapsed pediatric malignancies
Recruiting
- Conditions
- Progressive or relapsed pediatric malignancies
- Registration Number
- DRKS00011707
- Lead Sponsor
- niversitätsklinikum Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
• Age: 0 to <22 years
• Diagnosis: Recurrence or progression of any pediatric tumor
• signed ICF including information on whether germline information should be passed on to the patient and/or her/his legal guardians
• sufficient tumor material and peripheral blood sample
Exclusion Criteria
• primary diagnosis of a pediatric tumor
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • to determine the incidence of integrated molecular diagnoses including targetable alterations (DNA-methylation array and GPS) in the studied population
- Secondary Outcome Measures
Name Time Method • to determine the turnover time (time in days from receipt of complete submission to mailing of a report)<br>• to determine the frequency and type of a) targeted therapies initiated based upon the integrated molecular diagnosis, or b) other therapies initiated after receiving results from the PTT2.0 Analysis<br><br>Explorative<br>• OS (overall survival) and EFS (event free survival) of patients after PTT2.0 analysis, a) with or b) without targeted therapies initiated based upon the integrated molecular diagnosis<br>